Case report: Daratumumab treatment in pre-transplant alloimmunization and severe hemolytic anemia

Daratumumab, a CD38 monoclonal antibody that has been FDA-approved to treat multiple myeloma, has acquired popularity and is used off-label for both auto- and alloantibody mediated disorders, particularly in refractory/resistant circumstances. Much of the published data for its use in pediatric bloo...

Descripción completa

Detalles Bibliográficos
Autores principales: Pereda, Maria A., Hosahalli Vasanna, Smitha, Desai, Neha J., Deng, Victoria, Owusu-Ansah, Amma, Dallas, Mari H., Pateva, Irina, Dalal, Jignesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9744936/
https://www.ncbi.nlm.nih.gov/pubmed/36524117
http://dx.doi.org/10.3389/fimmu.2022.1055473

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9744936/
https://www.ncbi.nlm.nih.gov/pubmed/36524117
http://dx.doi.org/10.3389/fimmu.2022.1055473

Ejemplares similares